Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNM-Au8 open-label extension in ALS
NCT05299658Phase 2Active, not recruiting
- Sponsor
- Clene Inc.
- Start
- Nov 2021
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CNM-Au8 in amyotrophic lateral sclerosis (ALS), sponsored by Clene Inc.. Started Nov 2021; status: active, not recruiting.
02
Drugs
CNM-Au8
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05299658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299658.